Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 284

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

Open access
Tetzlaff, M.T., Messina, J.L., Stein, J.E., Xu, X., Amaria, R.N., Blank, C.U., van de Wiel, B.A., Ferguson, P.M., Rawson, R.V., Ross, M.I., Spillane, A.J., Gershenwald, J.E., Saw, R.P.M., van Akkooi, A.C.J., van Houdt, W.J., Mitchell, T.C., Menzies, A.M., Long, G.V., Wargo, J.A., Davies, M.A., Prieto, V.G., Taube, J.M., Scolyer, R.A.·2018·Annals of Oncology

Abstract

Background: Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical to standardize pathologic assessment and reporting of tumor response after this treatment. Methods: The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 assembled pathologists from academic centers to develop consensus guidelines for pathologic examination and reporting of surgical specimens from AJCC (8th edition) stage IIIB/C/D or oligometastatic stage IV melanoma patients treated with neoadjuvant-targeted or immune therapy. Patterns of pathologic response are provided context to inform these guidelines. Results: Based on our collective experience and guided by efforts in well-established neoadjuvant settings like breast cancer, procedures directing handling of pre- and post-neoadjuvant therapy-treated melanoma specimens are provided to facilitate comparison of findings across different trials and centers. Definitions of pathologic response are provided together with guidelines for reporting and quantifying the extent of pathologic response. Finally, the spectrum of histopathologic responses observed following neoadjuvant-targeted and immune-checkpoint therapy is described and illustrated. Conclusions: Standardizing pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy allows more robust stratification of patient outcomes. This includes recognizing the spectrum of histopathologic response patterns to neoadjuvant therapy and a standard approach to grading pathologic responses. Such an approach will facilitate comparison of results across clinical trials and inform ongoing correlative studies into the mechanisms of response and resistance to agents applied in the neoadjuvant setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy226

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 284

Metadata

Authors
Tetzlaff, M. T., Messina, J. L., Stein, J. E., Xu, X., Amaria, R. N., Blank, C. U., van de Wiel, B. A., Ferguson, P. M., Rawson, R. V., Ross, M. I., Spillane, A. J., Gershenwald, J. E., Saw, R. P. M., van Akkooi, A. C. J., van Houdt, W. J., Mitchell, T. C., Menzies, A. M., Long, G. V., Wargo, J. A., Davies, M. A., Prieto, V. G., Taube, J. M., & Scolyer, R. A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-08
Volume
29
Issue
8
Pages
1861-1868
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2810879984
Cited by
284
References
26
FWCI
5.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. https://app.cochat.ai/papers/10.1093/annonc/mdy226
The paper
Tetzlaff, M. T., Messina, J. L., Stein, J. E., Xu, X., Amaria, R. N., Blank, C. U., van de Wiel, B. A., Ferguson, P. M., Rawson, R. V., Ross, M. I., Spillane, A. J., Gershenwald, J. E., Saw, R. P. M., van Akkooi, A. C. J., van Houdt, W. J., Mitchell, T. C., Menzies, A. M., Long, G. V., Wargo, J. A., . . . Scolyer, R. A. (2018). Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology. https://doi.org/10.1093/annonc/mdy226

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.